Webinar 014

Download Webinar Registration Form

Dr Yurkovsky’s Webinar 014 – Recording (May 20th, 2013)

  1. Two Interesting updates
     
    Do you recall this patient presented in Webinar 001 with dermatitis, due to multiple chemical sensitivities, that “ruins my life” following conventional and alternative treatments for years? You may review his along with other cases on the Webinars page.

    I have not seen him in 10 months, (perhaps he was cured or quit FCT due to not seeing 100% resolution of his condition, yet?) until just recently.

    We will display:

    1. His current photo
    2. His quote concerning FCT
    3. His last prior treatment that also contained a very, very unusual isode

  2. A case of infertility
     
    of a young man with an extremely low sperm count presented at Webinar 010. We have just received his 2nd sperm analysis report since he started FCT and will display it along with its preceding FCT treatments(s). No pills to affect sperm count, either way, were administered.
     
  3. A case of a patient who was not responding initially to FCT
     
  4. The clinical use in both testing and therapy of a rather uncommon sarcode: Pelvic Diaphragm
     
    A longstanding and refractory case of seemingly just a prostate pathology.
     
  5. ‘My people perish for lack of knowledge’ – Hosea 4:6
     
    A case of a former FCT student, a biological dentist, who listened not to my admonishment in the past and instead, pursued false idols – ART (Autonomic Response Testing), Omura bi-digital o-ring test and their respective treatments. Today, he is a wheel chair bound invalid who had to give up a prosperous dental practice. He is only in his fifties.

    A not a very revealing, overall, revelation concerning ART experts’ response to my recent request for actual proofs of ART being such a ‘special’ bio-resonance testing.

We will cover as much of this webinar’s agenda as we can, without rushing, but at least we have condensed all of the new and old interesting cases in one program, for now.

Comments are closed.